



Supernus Pharmaceuticals, Inc.
Investor Relations Department
1550 East Gude Drive
Rockville, MD 20850
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: SUPN

Last Trade:	44.15
Trade Time:	4:00 PM ET Jun 23, 2017
Change:	0.50 (+1.145%)
Day Range	43.40 - 44.95
52-Week Range	17.25 - 44.95
Volume	686,153

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Supernus Pharmaceuticals extensive expertise in product development has been built over the past 20 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, upon our acquisition of substantially all the assets of Shire Laboratories Inc. in late 2005, as Supernus Pharmaceuticals.

... [\(more\)](#)

Stock Information



Press Releases [\[View all \]](#)

Jun 21, 2017

[Supernus Announces that its Partner Shire Receives FDA Approval for Mydavis™ for ADHD](#)

Jun 1, 2017

[Supernus to Present at Jefferies Healthcare Conference](#)

May 9, 2017

[Supernus Announces First Quarter 2017 Financial Results](#)

Apr 26, 2017

[Supernus to Host First Quarter 2017 Earnings Conference Call](#)

Apr 5, 2017

[Supernus Receives Final FDA Approval for Trokendi XR® for Migraine Prophylaxis in Adults and Adolescents](#)

Financials & Filings [\[View all \]](#)

[First Quarter Financial Results](#)

Mar 16, 2017

[Annual Report \(10-K\)](#)

Apr 27, 2017

[Proxy Statement \(DEF 14A\)](#)

May 9, 2017

[Quarterly Report \(10-Q\)](#)

Jan 20, 2017

[Quarterly Report \(10-Q\)](#)

Aug 5, 2016

[Quarterly Report \(10-Q\)](#)